Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England

Documenti analoghi

• The prognostic value of POD24 in relapsed/refractory follicular lymphoma—A SCHOLAR‐5 analysis
  di: Eve H. Limbrick‐Oldfield, et al.
  Pubblicazione: (2025)
• Real‐world characteristics and outcomes of patients with multiple myeloma receiving second‐line treatment in England
  di: Sally Moore, et al.
  Pubblicazione: (2024)
• Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma
  di: Abdullah N. M. Alqahtani, et al.
  Pubblicazione: (2024)
• Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B‐cell lymphoma in an adolescent patient
  di: Dasom Lee, et al.
  Pubblicazione: (2024)
• Isolated central nervous system relapse in mantle cell lymphoma
  di: Radu Chiriac, et al.
  Pubblicazione: (2025)